Penn Medicine Abramson Cancer Center


 

DLCL: Immune Modulation Therapy Including CAR-T, Bispecific Antibodies, and New Antibodies

10 views
May 2, 2022
0 Comments
Login to view comments. Click here to Login
2022 Updates in Care of the Hematologic Malignancies Patient